Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: Risk of new occurrence of atrial fibrillation and ischemic stroke

Abstract

Background: Patients with myocardial infarction (MI) are at risk of the development of atrial (Cardiol J 2014; 21, 5: 474-483)

CHA2DS2-VASc score is useful in predicting poor 12-month outcomes following myocardial infarction in diabetic patients without atrial fibrillation

“…They aid us in guiding antithrombotic therapy in AF patients. The individual score components not only predict AF-associated stroke risk but also are linked to the development of AF [12–14]. The CHADS 2 and CHA 2 DS 2 -VASc scores have been reported to identify post-STEMI patients at high risk of AF and ischemic stroke [14].…”

Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients?

“…Both scores showed to be predictive not only of thromboembolic stroke risk, but also adverse vascular function, CV and total death in the whole AF population [26][27][28]. Moreover, a predictive value of both scores was confirmed also in patients with other conditions, like ischemic heart disease or in patients with comorbidities also influencing thromboembolic risk profile [29][30][31].…”

Post myocardial infarction and atrial fibrillation: Thromboprophylaxis and risk stratification using the CHA2DS2-VASc score

“…Despite various guidelines, the results from Meier et al [8] highlight the lack of coherent management strategies among clinicians for AF patients who had received revascularization therapy for ACS. This may indicate persistent gaps in awareness among clinicians concerning management of ACS in AF patients, or the aversion of anticoagulation use due to perception of bleeding risk among this patient group who are usually older and generally frailer.…”

“…In the first article, Meier et al [8] utilized "real-world" data from the Berlin AFibACS Registry to identify over a 46-month period 1,295 AF patients who had suffered ACS, of which > 99% possessed significant stroke risk (CHA 2 DS 2 -VASc score > 1). Out of these, 888 (68.6%) AF-ACS patients had stent implantation, 7% only with balloon angioplasty, and the rest treated conservatively.…”

“…First, Maier et al [8] used the Berlin metropolitan registries to investigate the use of antiplatelet agents and OAC amongst AF patients who have experienced ACS. The second article by Lau et al [9] utilized a Hong Kong registry to investigate the possibility of using CHADS 2 and CHA 2 DS 2 -VASc score to predict new-onset AF among ST elevation myocardial infarction (STEMI) survivors.…”